Evaluation of Gut Microbiome Impact on Tacrolimus Pharmacokinetics in Healthy Volunteers

The primary objective of this study is to evaluate the **pharmacokinetics** of tacrolimus in relation to the gut microbiome in healthy volunteers. Understanding the influence of the gut microbiome on tacrolimus pharmacokinetics is clinically relevant as it may impact drug absorption, metabolism, and overall efficacy, potentially informing personalized dosing strategies and improving therapeutic outcomes.

The clinical trial involves a **pharmacokinetic study** conducted in **healthy volunteers**. The study population includes both male and female participants, with an age range categorized as adults. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected based on their general health status, ensuring they are free from any significant medical conditions. Lifestyle considerations such as diet, physical activity, and habits were not specified. The sponsor did not provide specific inclusion or exclusion criteria for this trial.

The clinical trial is designed to assess the influence of the **gut microbiome** on the pharmacokinetics of tacrolimus in healthy volunteers. This is a **Phase 3** trial, categorized as a pharmacokinetic study, and involves a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The trial is expected to commence recruitment on July 1, 2023, and is estimated to conclude by December 31, 2023, providing a comprehensive evaluation period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This initial visit will involve assessments to ensure participants meet the necessary health standards for inclusion in the study. Following the screening, participants will be randomly assigned to different study groups, with neither the participants nor the researchers aware of the group assignments, maintaining the double-blind nature of the trial.

Throughout the trial, participants will attend scheduled follow-up visits, which are critical for monitoring the pharmacokinetic parameters of tacrolimus and assessing any changes in the gut microbiome. These visits will include blood sampling, health evaluations, and compliance checks to ensure adherence to the study protocol. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data for analysis.

The expected length of participant involvement is approximately six months, aligning with the overall trial duration. Conditions that may lead to early termination from the study include non-compliance with the study protocol, adverse events that compromise participant safety, or withdrawal of consent. The trial is structured to maintain the highest ethical standards and scientific rigor, ensuring that the data collected will contribute valuable insights into the interaction between the gut microbiome and tacrolimus pharmacokinetics.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on July 1, 2023, and is estimated to conclude by December 31, 2023. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters are not specified. The trial will adhere to the standard protocols and methodologies typical of Phase 3 clinical trials, ensuring rigorous assessment of the treatment's efficacy. The trial's design and execution will follow established clinical guidelines to ensure the reliability and validity of the efficacy data collected.